Open original FDA record ↗Recall record
- FDA identifier
- Z-2095-2017
- Company in FDA record
- BioMerieux SA
- FDA classification date
- May 3, 2017
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
False susceptible results
Source facts
- Action
- bioMerieux sent an Urgent Product Safety Correction Notice on April 25, 2017 to U. S. consignees. The letter requested that they provide the notice to all appropriate personnel in the laboratory, asking them to identify any possible False Susceptible results. The letter included a Acknowledgment Form to be returned. On this notice the consignee will indicate the number of kits discarded. For customers with questions please contact their local bioMerieux Customer Service representative.
- Initiated
- 2017-04-25
- Root cause
- Under Investigation by firm
- Terminated
- 2022-02-24
- Distribution
- NATIONWIDE DISTRIBUTION TO AL, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, IL, IN, IA, KS, KY, LA, M, MA, MD, MI, MN, MS, MO, MT, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, and WY
- Recall number
- Z-2095-2017
- Recall status
- Terminated
- CDRH record ID
- 154758
- FDA classified
- 2017-05-03
- Recall event number
- 76983